VOGUE: Non-Inferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment

Clicks: 41
ID: 322774
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #47 of 324 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 324 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Antiretroviral therapy (ART) that achieves virologic suppression using fewer antiretroviral agents is an optimized approach to HIV treatment initiation. VOGUE is the first randomized, head-to-head study comparing the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as initial ART, including among individuals with high viral loads (VLs) and/or low CD4+ cell counts. Methods This phase 3b, randomized (1:1), open-label, non-inferiority study compared DTG/3TC vs BIC/FTC/TAF as first-line ART in adults with HIV-1. Participants were enrolled without baseline VL or CD4+ cell count restrictions and initiated treatment before availability of resistance testing results. The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL at Week 48 (Snapshot; -10% non-inferiority margin). Results Among 509 randomized participants (DTG/3TC, n=254; BIC/FTC/TAF, n=255), 47% had baseline VL ≥100,000 copies/mL and 16% had CD4+ cell count <200 cells/mm3. At Week 48, DTG/3TC demonstrated non-inferior efficacy to BIC/FTC/TAF, with HIV-1 RNA <50 copies/mL achieved in 89% and 92% of participants, respectively (adjusted difference, -3% [95% CI, -8%, 2%]). Median time to virologic suppression was rapid (4.1 weeks) in both groups. Confirmed virologic withdrawals were similar between groups (n=7 each), with no treatment-emergent resistance identified. Safety outcomes were comparable. Conclusions Dolutegravir/Lamivudine demonstrated non-inferior efficacy to BIC/FTC/TAF as initial ART, with no treatment-emergent resistance through Week 48. These findings establish DTG/3TC as an effective and simplified initial ART regimen across a broad clinical spectrum.
Reference Key
openalex_W7171558457 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jade Ghosn, Federico Pulido, Gustavo Lopardo, Anita Olczak, Diego Ripamonti, Charlotte Martin, Orlando Paredes Ceballos, Hartmut Stocker, J Mendez, Hiroyuki Gatanaga, Symeon Metallidis, Daniel Elbirt, Gary Whitlock, José Ignacio Mateo González, Perry Mohammed, Kehui Wang, Richard Grove, Ruolan Wang, Adelaide Jewell, Kenneth Sutton, Emilie R Elliot, Riya Moodley, Rebecca Borsi, Bryn Jones, Michelle Kisare, Piotr Budnik, Jean van Wyk
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag471
URL
https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofag471/70252090/ofag471.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.